Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Like many of the start-ups in the bio sector, the Midatech Biogune Company depends on strong investments during the initial years after the founding of the company and a long period of development, trials and licensing until profits can be obtained to commercialise its product.
In exchange, it promises to achieve an objective as ambitious as providing life to millions of people all over the world who have to take insulin daily to control their diabetes. How? By means of a small adhesive bandage placed on the inside of the cheek which releases gold nanoparticles which transport the hormone.
Midatech Biogune, strategically located beside CIC Biogune at the Bizkaia Technology Park, is a bio-nanotechnological company based on a Soledad Penad?s technology, who is currently group leader at CIC biomaGUNE, but led a research group at the CSIC in 2000. Its level of development makes it one of the Basque Country?s most promising biotechnology companies.
Justin Barry, director of Midatech Biogune, explains the origin of the company from his office, at the back of an office which suggests hyperactivity: The director of the British firm, Midatech, Professor Thomas Rademacher, who worked jointly with Soledad Penad?s in 2000, saw an opportunity in the technology she developed since the minuscule size of the nanoparticles developed make its work possible?.
http://www.nanowerk.com/news2/newsid=27075.php
In exchange, it promises to achieve an objective as ambitious as providing life to millions of people all over the world who have to take insulin daily to control their diabetes. How? By means of a small adhesive bandage placed on the inside of the cheek which releases gold nanoparticles which transport the hormone.
Midatech Biogune, strategically located beside CIC Biogune at the Bizkaia Technology Park, is a bio-nanotechnological company based on a Soledad Penad?s technology, who is currently group leader at CIC biomaGUNE, but led a research group at the CSIC in 2000. Its level of development makes it one of the Basque Country?s most promising biotechnology companies.
Justin Barry, director of Midatech Biogune, explains the origin of the company from his office, at the back of an office which suggests hyperactivity: The director of the British firm, Midatech, Professor Thomas Rademacher, who worked jointly with Soledad Penad?s in 2000, saw an opportunity in the technology she developed since the minuscule size of the nanoparticles developed make its work possible?.
http://www.nanowerk.com/news2/newsid=27075.php